BioGaia ProTectis baby drops and the BioGaia ProTectis tablets contain BioGaia’s patented and researched probiotic strain Lactobacillus reuteri Protectis.
BioGaia Gastrus is a new product that is currently being investigated in patients with Helicobacter pylori infection.
BioGaia president Peter Rothschild said that since last year the company has been focusing on getting its products into the BRIC markets.
"China is of course a market with tremendous potential, but also with many challenges in terms of achieving sufficient distribution and penetration, but with Keyuan as our partner we are confident that we will be successful also in China in the long term," Rothschild added.
Beijing Keyuan Xinhai Pharmaceutical is a wholly owned subsidiary of Shanghai Pharmaceuticals.